초록 ▼

A process is described in which the waste gas from the production of acetylene is employed in the Fischer-Tropsch synthesis of hydrocarbon liquids. The process consists of the steps of collecting the waste gas, compressing it to the proper pressure, passing the compressed gas into a reactor containi

A process is described in which the waste gas from the production of acetylene is employed in the Fischer-Tropsch synthesis of hydrocarbon liquids. The process consists of the steps of collecting the waste gas, compressing it to the proper pressure, passing the compressed gas into a reactor containing a Fischer-Tropsch catalyst under the proper conditions of temperature, pressure, and space velocity, and collecting the liquid products thereby formed from the waste gas stream.

대표청구항 ▼

A process is described in which the waste gas from the production of acetylene is employed in the Fischer-Tropsch synthesis of hydrocarbon liquids. The process consists of the steps of collecting the waste gas, compressing it to the proper pressure, passing the compressed gas into a reactor containi

A process is described in which the waste gas from the production of acetylene is employed in the Fischer-Tropsch synthesis of hydrocarbon liquids. The process consists of the steps of collecting the waste gas, compressing it to the proper pressure, passing the compressed gas into a reactor containing a Fischer-Tropsch catalyst under the proper conditions of temperature, pressure, and space velocity, and collecting the liquid products thereby formed from the waste gas stream. B>pAr or X(CH2)pR4or a group of formula (a): Ar is a group of formula (b) or (c): or Ar is naphthyl, which may be unsubstituted or substituted by one or more R7or R8groups; A is C=O or (C(R4)2)m; each B is --CH2--; R4is hydrogen or C1-6alkyl, with the proviso that when R7or R9is X--(CR4)p--OR4,X is (CH2)pand p is 0 then R4is not C1-6alkyl; R5is hydrogen or C1-10alkyl or Ar, both of which may be unsubstituted or substituted by one or two Cl, F, Br, hydroxy, XC1-5alkyl, C1-5alkyl, NO2,tetrazol-5-yl optionally substituted by C1-6alkyl, or R5is N(R4)2; R6is R10,CO2R11,CO2C(R10)2O(CO)XR11,PO3(R11)2,SO2NR11R10,NR11SO2R10,CONR11SO2R10,SO3R11,S(O)qR11,S(O)qN(R11)C(O)R10,S(O)qN(R11)S(O)qR10,C(O)N(R11)C(O)R10,N(R11)C(O)R10,N(R11)2,N(R11)C(O)NR11,P(O)(OR11)R11,CN, --CO2(CH2)mC(O)N(R4)2,C(R10)2N(R11)2,C(O)N(R4)2,OR4or tetrazolyl optionally substituted by C1-6 alkyl, with the proviso that when R7or R9is --X--(CH2)p--R6,p is 0 and X is (CH2)pthen R6is not S(O)qR11; R7and R9are independently R10,OH, C1-8alkoxy, S(O)qR10,Br, F, I, Cl, CF3,NO2,NHCOR4,R12CO2R11,--X--R13--Y, --X(CR4)pR4,S(CH2)pCO2H, (CH2)pX--R13--, X(CH2)pCONR11SO2R10,(CH2)pXCONR11SO2R10or X(CH2)pR6wherein each methylene group within --X(CH2)qR6may be unsubstituted or substituted by one or two --(CH2)pAr groups; R8is hydrogen, R10,OH, C1-5alkoxy, S(O)qR10,N(R4)2,Br, F, I, Cl or NHCOR4wherein the C1-5alkoxy may be unsubstituted or substituted by OH, methoxy or halogen; R10is hydrogen, Ar, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, all of which may be unsubstituted or substituted by one or more OH,CH2OH, N(R4)2or halogen; or R10is N(R4)2; R11is independently hydrogen, C1-10alkyl, C2-10alkenyl or C2-8alkynyl, all of which may be unsubstituted or substituted by one or more OH, N(R4)2,CO2R14,halogen or XC1-5alkyl; or R11is (CH2)pAr; R12is divalent Ar, C1-10alkylene, C1-10alkylidene, C2-10alkenylene, C2-10alkynylene, all of which may be unsubstituted or substituted by one or more of OH, CH2OH, N(R4)2or halogen; R13is selected from the group consisting of: (1) a bond, (2) when R13is a linking group, selected from the group consisting of C1-10alkylene, C1-10alkenylene, C1-10alkylidene, C1-10alkynylene, all of which may be linear or branched, or phenylene, all of which may be unsubstituted or substituted by one or more OH, N(R4)2,COOH or halogen, and (3) when R13is a terminal group, selected from the group consisting of C1-10alkyl, C1-10alkenyl, C1-10alkynyl, all of which may be linear or branched, or phenyl, all of which may be unsubstituted or substituted by one or more OH, N(R4)2,COOH or halogen, with the proviso that when R7or R9is --(CH2)p--X--R13,p is 0 and X is O then R13is not a linear or branched alkyl chain of 1 to 8 carbon atoms; R14is hydrogen, C1-6alkyl, C2-6alkenyl or C2-7alkynyl; X is (CH2)p,O, NR4or S(O)p; Y is CH3or X(CH2)pAr, with the proviso that when R7or R9is X--R13--Y, X is O and R13is a bond, then Y is not CH3; q is zero, one or two; p is an integer from 0 to 6; m is 1, 2 or 3; n is 1 to 4; x is 0 to 4; y is 1 or 2; the dotted line signifies the optional presence of a bond such that it represents a single or double bond. 2. A method of treating a prostaglandin E mediated disease which comprises administering to a mammalian patient in need of such treatment or prevention a compound of formula I: wherein: R is a group Ar as defined hereinafter; R1is hydrogen, hydroxy, C1-6alkyl, C1-6alkoxy, X(CH2)pAr, or a methylenedioxy group attached to two adjacent ring carbon atoms; R2is --(CH2)xC(O)N(R4)S(O)yR5,--(CH2)xS(O))yN(R4)C(O)R5,--(CH2)xC(O)N(R4)C(O)R5,--(CH2)xS(O)yN(R4)S(O)yR5,--(CH2)xCO2R4,or tetrazol-5-yl optionally substituted by C1-6alkyl; R3is X(CH2)pAr or X(CH2)pR4or a group of formula (a): Ar is a group of formula (b) or (C): or Ar is naphthyl, which may be unsubstituted or substituted by one or more R7or R8groups; A is C=O or (C(R4)2)m; each B is --CH2--; R4is hydrogen or C1-6alkyl, with the proviso that when R7or R9is X--(CR4)p--OR4,X is (CH2)pand p is 0 then R4is not C1-6alkyl; R5is hydrogen or C1-6alkyl or Ar, both of which may be unsubstituted or substituted by one or two Cl, F, Br, hydroxy, XC1-5alkyl, C1-5alkyl, NO2,tetrazol-5-yl optionally substituted by C1-6alkyl, or R5is N(R4)2; R6is R10,CO2R11,CO2C(R10)2O(CO)XR11,PO3(R11)2,SO2NR11R10,NR11SO2R10,CONR11SO2R10,SO3R11,S(O)qR11,S(O)qN(R11)C(O)R10,S(O)qN(R11)S(O)qR10,C(O)N(R11)C(O)R10,N(R11)C(O)R10,N(R11)2,N(R11)C(O)NR11,P(O)(OR11)R11,CN, --CO2(CH2)mC(O)N(R4)2,C(R10O)2